Déprescription des agonistes des récepteurs des benzodiazépines: Lignes directrices de pratique clinique fondées sur les données probantes

Translated title of the contribution: Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline

Kevin Pottie, Wade Thompson, Simon Davies, Jean Grenier, Cheryl A. Sadowski, Vivian Welch, Anne Holbrook, Cynthia Boyd, Robert Swenson, Andy Ma Barbara Farrell

Research output: Contribution to journalReview articlepeer-review


Objective To develop an evidence-based guideline to help clinicians make decisions about when and how to safely taper and stop benzodiazepine receptor agonists (BZRAs); to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review, and endorsement processes. Methods The overall team comprised 8 clinicians (1 family physician, 2 psychiatrists, 1 clinical psychologist, 1 clinical pharmacologist, 2 clinical pharmacists, and 1 geriatrician) and a methodologist; members disclosed conflicts of interest. For guideline development, a systematic process was used, including the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Evidence was generated by conducting a systematic review of BZRA deprescribing trials for insomnia, as well as performing a review of reviews of the harms of continued BZRA use and narrative syntheses of patient preferences and resource implications. This evidence and GRADE quality of evidence ratings were used to generate recommendations. The team refined guideline content and recommendations through consensus and synthesized clinical considerations to address front-line clinician questions. The draft guideline was reviewed by clinicians and stakeholders. Recommendations We recommend that deprescribing (tapering slowly) of BZRAs be offered to elderly adults (≥65 years) who take BZRAs, regardless of duration of use, and suggest that deprescribing (tapering slowly) be offered to adults aged 18 to 64 who have used BZRAs for more than 4 weeks. These recommendations apply to patients who use BZRAs to treat insomnia on its own (primary insomnia) or comorbid insomnia where potential underlying comorbidities are effectively managed. This guideline does not apply to those with other sleep disorders or untreated anxiety, depression, or other physical or mental health conditions that might be causing or aggravating insomnia. Conclusion Benzodiazepine receptor agonists are associated with harms, and therapeutic effects might be short term. Tapering BZRAs improves cessation rates compared with usual care without serious harms. Patients might be more amenable to deprescribing conversations if they understand the rationale (potential for harm), are involved in developing the tapering plan, and are offered behavioural advice. This guideline provides recommendations for making decisions about when and how to reduce and stop BZRAs. Recommendations are meant to assist with, not dictate, decision making in conjunction with patients.

Translated title of the contributionDeprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline
Original languageFrench
Pages (from-to)339-351+e209-e224
JournalCanadian Family Physician
Issue number5
StatePublished - May 1 2018

ASJC Scopus subject areas

  • Family Practice


Dive into the research topics of 'Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline'. Together they form a unique fingerprint.

Cite this